Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer

por Kazandjian, Dickran, Blumenthal, Gideon M., Luo, Lola, He, Kun, Fran, Ingrid, Lemery, Steven, Pazdur, Richard
Publicado 2016